Navigation Links
Rejected Alzheimer's drug shows new potential
Date:7/31/2012

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of act
'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gay Adults Rejected by Parents Have Worse Health, Study Finds
2. Landmark HIV treatment-as-prevention study shows additional health benefits, cost-effectiveness
3. Weight Control Can Cut Womens Diabetes Risk, Study Shows
4. Mindfulness meditation reduces loneliness in older adults, Carnegie Mellon study shows
5. SEARCH study shows 1-year drop in HIV virus levels in rural Ugandan parish after campaign
6. Research shows potential of microneedles to target therapeutics to the back of the eye
7. 32-country study shows that type 2 diabetes drug is clinically effective for long-term use
8. Benefits of HIV drugs rise -- but less than previously believed, Penn study shows
9. Alzheimers Drug Shows Promise in Early Trial
10. Study shows colon and rectal tumors constitute a single type of cancer
11. Spouses of severe-sepsis patients at high risk of depression, U-M study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... considered nearly eradicated. Each year only a few hundred ... of Bonn, together with colleagues from Gabon, are reporting ... resist the vaccine protection to a considerable extent was ... in 2010. The pathogen could also potentially have infected ... the magazine PNAS . , The polio epidemic ...
(Date:8/21/2014)... Maryland (PRWEB) August 21, 2014 As ... the U.S. Pharmacopeial Convention (USP) has joined with the ... threat posed by the illegal online sale of medicines. ... benefits of medicines and foods is a core mission ... health around the world,” said Ronald T. Piervincenzi, chief ...
(Date:8/21/2014)... It's a terrible thing when a young adult, ... substance abuse issue. When that happens to a teenager in ... reliable help from the qualified substance abuse therapists at a ... easy for those young adults living in Pompano Beach, FL ... , Thankfully there is a new helpline operating for ...
(Date:8/21/2014)... CA (PRWEB) August 21, 2014 David ... is a short but powerful collection of quotes from ... uplift and inspire other budding entrepreneurs on their challenging ... proud to announce the inclusion of President and Founder ... from highly successful and self-made celebrities such as Oprah ...
(Date:8/21/2014)... by T-type calcium channels in the thalamic reticular ... calcium. These channels enable thalamic reticular nucleus neurons ... enter a hyper-excited state. , In order to ... seizures, the researchers conducted an experiment to induce ... to delete the T-type calcium channel CaV3.3. The ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2
... , FRIDAY, July 29 (HealthDay News) -- Some ethnic groups are ... organs as they gain weight, according to a new study. ... artery disease, is more common among people from South Asia, the ... journal PLoS ONE . "The new study showed South ...
... may also be contributing to hearing loss. Scientists mapped ... The distinctive roar of a Harley,s engine is ... noise for motorcyclists is actually generated by air whooshing ... sound can exceed safe levels. Now, scientists have identified ...
... testing at local emergency departments shows that hospitals miss opportunities ... with HIV, even when a regular testing program is in ... to the July issue of Annals of Emergency Medicine ... (CDC). The supplement includes a series of studies on HIV ...
... When people recognize voices, part of what helps make ... differently. But individuals with dyslexia don,t experience this familiar ... impairment." Tyler Perrachione with the Massachusetts Institute of ... language use the same words, they say those words ...
... protect skin cells from the sun,s ultraviolet radiation, according ... Barcelona and the CSIC (Spanish National Research Council). The ... in sun protection products. Ultraviolet (UV) rays emitted ... skin complaints, causing skin cancer, sunburn and solar erythema, ...
... The U.S. Food and Drug Administration should gather the ... the 35-year-old 510(k) clearance process for medical devices, says a ... process lacks the legal basis to be a reliable premarket ... devices and cannot be transformed into one, concluded the committee ...
Cached Medicine News:Health News:Some Ethnic Groups More Vulnerable to Dangerous Fat 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 3Health News:Dissecting dyslexia: Linking reading to voice recognition 2Health News:Dissecting dyslexia: Linking reading to voice recognition 3Health News:Grapes protect against ultraviolet radiation 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 3
(Date:8/21/2014)... CVS Caremark Corporation (NYSE: CVS ) announced today ... in connection with its previously announced cash tender offers (the ... and all of its 6.250% Senior Notes due 2027 (the ... amount of its 6.125% Senior Notes due 2039, 5.750% Senior ... the "Maximum Tender Offer Notes" and together with the Any ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... , Aug. 21, 2014  SI-BONE, Inc. ( ... that pioneered the use of the iFuse Implant System, ... for fusion of the sacroiliac (SI) joint, announced that ... update to its Lumbar Fusion Medical Policy No. 91590-R4 ... procedure.  The policy states that the fusion procedure, which ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: